Biohaven Pharmaceutical Valuation
| BHVN Stock | USD 11.50 0.28 2.38% |
At this time, the firm appears to be undervalued. Biohaven Pharmaceutical shows a prevailing Real Value of $13.42 per share. The current price of the firm is $11.5. Our model approximates the value of Biohaven Pharmaceutical from analyzing the firm fundamentals such as Current Valuation of 1.62 B, shares owned by insiders of 9.52 %, and Return On Equity of -5.22 as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Biohaven Pharmaceutical's price fluctuation is somewhat reliable at this time. Calculation of the real value of Biohaven Pharmaceutical is based on 3 months time horizon. Increasing Biohaven Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biohaven Pharmaceutical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biohaven Stock. However, Biohaven Pharmaceutical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 11.5 | Real 13.42 | Target 20.94 | Hype 12.9 |
The intrinsic value of Biohaven Pharmaceutical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biohaven Pharmaceutical's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biohaven Pharmaceutical Holding helps investors to forecast how Biohaven stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biohaven Pharmaceutical more accurately as focusing exclusively on Biohaven Pharmaceutical's fundamentals will not take into account other important factors: Biohaven Pharmaceutical Cash |
|
Biohaven Pharmaceutical Total Value Analysis
Biohaven Pharmaceutical Holding is currently anticipated to have valuation of 1.62 B with market capitalization of 1.56 B, debt of 36.58 M, and cash on hands of 23.21 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biohaven Pharmaceutical fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.62 B | 1.56 B | 36.58 M | 23.21 M |
Biohaven Pharmaceutical Asset Utilization
One of the ways to look at asset utilization of Biohaven is to check how much profit was generated for every dollar of assets it reports. Biohaven Pharmaceutical Holding shows a negative utilization of assets of -1.06 percent, losing $0.0106 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Biohaven Pharmaceutical Holding shows how discouraging it operates for each dollar spent on its assets.Biohaven Pharmaceutical Profitability Analysis
Taking into consideration Biohaven Pharmaceutical's profitability measurements, Biohaven Pharmaceutical Holding may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Biohaven Pharmaceutical's ability to earn profits and add value for shareholders.Net Loss | First Reported 2017-03-31 | Previous Quarter -198.1 M | Current Value -173.4 M | Quarterly Volatility 85.3 M |
For Biohaven Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Biohaven Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Biohaven Pharmaceutical utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Biohaven Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Biohaven Pharmaceutical over time as well as its relative position and ranking within its peers.
Biohaven Pharmaceutical Earnings per Share Projection vs Actual
By analyzing Biohaven Pharmaceutical's earnings estimates, investors can diagnose different trends across Biohaven Pharmaceutical's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Biohaven Pharmaceutical Holding is based on EPS before non-recurring items and includes expenses related to employee stock options.Biohaven Pharmaceutical Ownership Allocation
Biohaven Pharmaceutical holds a total of 132.69 Million outstanding shares. Over half of Biohaven Pharmaceutical's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Biohaven Pharmaceutical Profitability Analysis
Net Loss for the year was (846.42 M) with profit before overhead, payroll, taxes, and interest of 0.About Biohaven Pharmaceutical Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Biohaven Pharmaceutical Holding. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Biohaven Pharmaceutical based exclusively on its fundamental and basic technical indicators. By analyzing Biohaven Pharmaceutical's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Biohaven Pharmaceutical's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biohaven Pharmaceutical. We calculate exposure to Biohaven Pharmaceutical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biohaven Pharmaceutical's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -3.5 M | -3.4 M |
Biohaven Pharmaceutical Current Valuation Indicators
Biohaven Pharmaceutical's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Biohaven Pharmaceutical's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Biohaven Pharmaceutical, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Biohaven Pharmaceutical's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Biohaven Pharmaceutical's worth.When determining whether Biohaven Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biohaven Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biohaven Pharmaceutical Holding Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biohaven Pharmaceutical Holding Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Will Biotechnology sector continue expanding? Could Biohaven diversify its offerings? Factors like these will boost the valuation of Biohaven Pharmaceutical. Projected growth potential of Biohaven fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Biohaven Pharmaceutical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Biohaven Pharmaceutical requires distinguishing between market price and book value, where the latter reflects Biohaven's accounting equity. The concept of intrinsic value - what Biohaven Pharmaceutical's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Biohaven Pharmaceutical's price substantially above or below its fundamental value.
It's important to distinguish between Biohaven Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biohaven Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biohaven Pharmaceutical's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.